Patient-specific B-cell receptor idiotype (BCR idiotype) (BCR idiotype)

The patient-specific B-cell receptor (BCR) idiotype represents the unique set of antigenic determinants located within the variable regions of the immunoglobulin molecule expressed by a malignant B-cell clone (Levy et al., 2011, PubMed: 21460471). Since each B-cell lymphoma arises from a single transformed cell, all progeny express the same unique BCR, making the idiotype a highly specific tumor neoantigen that is absent from healthy B-cells and other tissues (Bendandi, 2009, PubMed: 19381125). In therapeutic applications, the idiotype is typically harvested from the patient's own tumor cells and formulated into a personalized vaccine, such as BiovaxID or MyVax (Schuster et al., 2011, PubMed: 21734235). These vaccines are often conjugated to a carrier protein like Keyhole Limpet Hemocyanin (KLH) and administered with adjuvants like Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) to stimulate a host immune response against the lymphoma (Inoges et al., 2006, PubMed: 16446376). Despite the high specificity of this target, clinical success has been limited by manufacturing challenges and the need for robust immune activation in often immunocompromised patients (Kwak, 2010, PubMed: 20530285).

Other names

Tumor-specific idiotypeClonal immunoglobulinId proteinB-cell receptor variable regionPersonalized lymphoma antigen

Active immunotherapy involving the administration of patient-specific idiotype proteins to induce a polyclonal immune response (both humoral and cellular) against the unique variable regions of the malignant B-cell receptor (Levy et al., 2011, PubMed: 21460471).